tetano
Editor, Senior Moderator
J Thromb Thrombolysis. 2020 Apr 3. doi: 10.1007/s11239-020-02105-8. [Epub ahead of print]
Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2.
Yin S[SUP]1[/SUP], Huang M[SUP]2[/SUP], Li D[SUP]3[/SUP], Tang N[SUP]4[/SUP].
Author information
Abstract
Severe coronavirus disease 2019 (COVID-19) is commonly complicated with coagulopathy, the difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 has not been analyzed. Coagulation results and clinical features of consecutive patients with severe pneumonia induced by SARS-CoV2 (COVID group) and non-SARS-CoV2 (non-COVID group) in Tongji hospital were retrospectively analyzed and compared. Whether patients with elevated D-dimer could benefit from anticoagulant treatment was evaluated. There were 449 COVID patients and 104 non-COVID patients enrolled into the study. The 28-day mortality in COVID group was approximately twofold of mortality in non-COVID group (29.8% vs. 15.4%, P = 0.003), COVID group were older (65.1 ? 12.0 vs. 58.4 ? 18.0, years, P < 0.001) and with higher platelet count (215 ? 100 vs. 188 ? 98, ?10[SUP]9[/SUP]/L, P = 0.015), comparing to non-COVID group. The 28-day mortality of heparin users were lower than nonusers In COVID group with D-dimer > 3.0 μg/mL (32.8% vs. 52.4%, P = 0.017). Patients with severe pneumonia induced by SARS-CoV2 had higher platelet count than those induced by non-SARS-CoV2, and only the former with markedly elevated D-dimer may benefit from anticoagulant treatment.
KEYWORDS:
Coagulopathy; Coronavirus disease 2019; D-dimer; Severe pneumonia
PMID:32246317DOI:10.1007/s11239-020-02105-8
Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2.
Yin S[SUP]1[/SUP], Huang M[SUP]2[/SUP], Li D[SUP]3[/SUP], Tang N[SUP]4[/SUP].
Author information
Abstract
Severe coronavirus disease 2019 (COVID-19) is commonly complicated with coagulopathy, the difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 has not been analyzed. Coagulation results and clinical features of consecutive patients with severe pneumonia induced by SARS-CoV2 (COVID group) and non-SARS-CoV2 (non-COVID group) in Tongji hospital were retrospectively analyzed and compared. Whether patients with elevated D-dimer could benefit from anticoagulant treatment was evaluated. There were 449 COVID patients and 104 non-COVID patients enrolled into the study. The 28-day mortality in COVID group was approximately twofold of mortality in non-COVID group (29.8% vs. 15.4%, P = 0.003), COVID group were older (65.1 ? 12.0 vs. 58.4 ? 18.0, years, P < 0.001) and with higher platelet count (215 ? 100 vs. 188 ? 98, ?10[SUP]9[/SUP]/L, P = 0.015), comparing to non-COVID group. The 28-day mortality of heparin users were lower than nonusers In COVID group with D-dimer > 3.0 μg/mL (32.8% vs. 52.4%, P = 0.017). Patients with severe pneumonia induced by SARS-CoV2 had higher platelet count than those induced by non-SARS-CoV2, and only the former with markedly elevated D-dimer may benefit from anticoagulant treatment.
KEYWORDS:
Coagulopathy; Coronavirus disease 2019; D-dimer; Severe pneumonia
PMID:32246317DOI:10.1007/s11239-020-02105-8